Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2024 Earnings Call Transcript

Page 4 of 4

Chris Anzalone: In that, in that Phase 3 study we are studying people with genetically confirmed FCS and those patients with clinical STS, if you will, which is patients with the triglycerides above 880 and history of pancreatitis. That population we are studying.

William Pickering : Thank you.

Chris Anzalone: You’re welcome.

Operator: And I would now like to turn the conference back to Chris Anzalone for closing remarks.

Chris Anzalone: Thanks very much for tuning in. today. We look forward to speaking with you over the next quarter. And those of you who are in Southern California hope you stay dry.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.

Follow Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)

Page 4 of 4